Economic costs of treating high blood pressure in the Adamaoua region of Cameroon
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20252825Keywords:
Economic cost, High blood pressure, Adamaoua-CameroonAbstract
Background: High blood pressure constitutes a major public health problem in Cameroon with a prevalence of 30.9% making it a major driver of healthcare costs. This study evaluated the economic cost of high blood pressure treatment in the Adamaoua region, in Cameroon.
Methods: A cross-sectional medico-economic evaluation using the cost analysis was conducted. Costing approach used a bottom-up micro-costing with unit costs for diagnostic and therapeutic interventions and nonmedical and indirect costs. An average cost of treatment per patient was presented as mean, median and standard deviation. The linear regression was used to identify factors influencing the cost variations. The significance threshold was set at p˂5%.
Results: A total number of 179 patients were sampled, including 112 patients with uncomplicated and 67 with complicated high blood pressure. The average annual total economic costs of uncomplicated high blood pressure to patients were estimated at XAF 220,276.76±75,743 (US$363.15±124.87) with the direct medical costs representing the highest proportion with (89.4%), following by the total indirect costs (7.3%), while the economic costs of treating complicated high blood pressure were estimated at XAF 346,516.05±292,081 (US$571.27±481.53) which mainly made up of direct medical costs (70.49%) followed by direct nonmedical cost (21.67%). Factors such as hospitalization, diet and transportation were statistically significant; while 33% of variability in expenses was related to hospitalization.
Conclusions: The economic costs of uncomplicated and complicated high blood pressure imply the policy for eliminating the financial barriers by including the treatment of high blood pressure in the second phase of the universal health coverage.
Metrics
References
Lien CW, Lee YH, Lu CW, Chang YC, Lin YS, Cheng HM, et al. Definition, prevalence, and economic impacts of hypertension on the elderly population. J Formosan Med Assoc. 2025;124(1):4-9. DOI: https://doi.org/10.1016/j.jfma.2025.02.020
Centers for Disease Control and Prevention. Estimated hypertension prevalence, treatment and control among US adults. 2023. Available at: https://millionhearts.hhs.gov/data-reports/hypertens ion-prevalence.html. Accessed on 24 May 2025.
Simões Corrêa Galendi J, Leite RGOF, Banzato LR, Nunes-Nogueira VDS. Effectiveness of Strategies for Nutritional Therapy for Patients with Type 2 Diabetes and/or Hypertension in Primary Care: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022;19(7):4243. DOI: https://doi.org/10.3390/ijerph19074243
Kifle ZD, Adugna M, Chanie GS, Mohammed A. Prevalence and associated factors of hypertension complications among hypertensive patients at University of Gondar Comprehensive Specialized Referral Hospital. Clin Epidemiol Global Health. 2022;13:100951.
Ahmad SN, Gul I, Sultan ST. Prevalence and associated factors of hypertension complications among hypertensive patients: A hospital-based study. Int J Acad Med Pharm. 2023;5(1):34-8.
World Health Organization. First WHO report on the devastating global impact of HBP or hypertension and ways to stop it. 2023. Available at: https://www. who.int/news/item/19-09-2023-first-who-report-details-devastating-impact-of-hypertension-and-ways-to-stop-it. Accessed on 24 May 2025.
Tesfa E, Demeke D. Prevalence of and risk factors for hypertension in Ethiopia: A systematic review and meta‐analysis. Health Sci Rep. 2021;4(3):e372. DOI: https://doi.org/10.1002/hsr2.372
Aovare P, Abdulai K, Laar A, van der Linden EL, Moens N, Richard E, et al. Assessing the Effectiveness of mHealth Interventions for Diabetes and Hypertension Management in Africa: Systematic Review and Meta-Analysis. JMIR Mhealth Uhealth. 2023;11:e43742. DOI: https://doi.org/10.2196/43742
Guwatudde D, Nankya-Mutyoba J, Kalyesubula R, Laurence C, Adebamowo C, Ajayi I, et al. The burden of hypertension in sub-Saharan Africa: a four-country cross sectional study. BMC Public Health. 2015;15:1211. DOI: https://doi.org/10.1186/s12889-015-2546-z
Ferdinand KC. Uncontrolled hypertension in sub‐Saharan Africa: Now is the time to address a looming crisis. J Clin Hypertens. 2020;22(11):2111. DOI: https://doi.org/10.1111/jch.14046
Mekonene M, Baye K, Gebremedhin S. Epidemiology of hypertension among adults in Addis Ababa, Ethiopia. Prev Med Rep. 2023;32:102159. DOI: https://doi.org/10.1016/j.pmedr.2023.102159
Fouda H, Ashuantang G, Kaze F, Halle MP. Survival in chronic hemodialysis in Cameroon. Pan Afr Med J. 2017;26:97. DOI: https://doi.org/10.11604/pamj.2017.26.97.9658
Richardson C, Battle SJ, DiPette DJ. Population-based approaches to increase hypertension control: an urgent need. Hypertens Res. 2025;48:1195-7. DOI: https://doi.org/10.1038/s41440-024-02022-w
Daroudi R, AkbariSari A, Zamandi M, Shahali Z. Economic burden of hypertension in Iran: a prevalence-based cost of illness study. BMJ Open. 2025;15(6):e099322. DOI: https://doi.org/10.1136/bmjopen-2025-099322
Kazi DS, Elkind MSV, Deutsch A. Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050: A Presidential Advisory From the American Heart Association. Circulation. 2024;150:4. DOI: https://doi.org/10.1161/CIR.0000000000001258
Drummond M. Cost- of- Illness Studies. Pharmacoeconomics. 1992;2:1-4. DOI: https://doi.org/10.2165/00019053-199202010-00001
Graden S. National estimate of cost of illness for hypertension and non- persistence with drug therapy using the medical expenditure panel survey. The Ohio State University. 2003.
Hodgson TA, Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Med Care. 2001;39:599-615. DOI: https://doi.org/10.1097/00005650-200106000-00008
Zamandi M, Daroudi R, Sari AA. Direct Costs of Hypertension Treatment in Iran. Iran J Public Health. 2023;52:1973-83. DOI: https://doi.org/10.18502/ijph.v52i9.13579
Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA. 1989;262:2879-86. DOI: https://doi.org/10.1001/jama.1989.03430200123038
Paczkowska A, Koligat D, Nowakowska E, Hoffmann K, Bryl W. Analysis of direct costs of hypertension treatment among adolescents in Poland. Acta Pol Pharm. 2014;71(1):197-203.
Alefan Q, Ibrahim MIM, Razak T. Cost of treating hypertension in Malaysia. Age (Dordr). 2009;45.
Zhai Y, Hu JP, Kong LZ, Zhao WH, Chen CM. Economic burden of coronary heart disease and stroke attributable to hypertension in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2006;27(9):744-7.
Dia SA, Mohamed AS, Ndoye EHO. Prevalence of HBP in the workplace: the case of the Alucam group in Cameroon. Ann Afr Med. 2019;12:4.
Asakura E, Ademi Z, Liew D, Zomer E. Productivity burden of hypertension in Japan. Hypertens Res. 2021;44(11):1524-33. DOI: https://doi.org/10.1038/s41440-021-00731-0
Kuate TC, Kenmogne KM, Doumbe J. Variations and determinants of the cost of hospital care for stroke in Douala (Cameroon). Health Sci Dis. 2016;17(4):730.
Siddikatou D, Djomou N, Kafack F, Ouankou N, Ndom S, Yonta K, et al. Prevalence and Associated Factors of HBP in a Cameroonian Community. Health Sci Dis. 2024;25:2.
Jingi A, Dzudie A, Noubiap JJ, Menanga AP, Aminde L, Fesuh B, et al. [PS 03-24] hypertension prevalence, awareness and control in Cameroon: a systematic review with projections for 2025 and 2035. J Hypertens. 2016;34:e132-3. DOI: https://doi.org/10.1097/01.hjh.0000500234.06930.00
Hou HJ, Cong TZ, Cai Y, Ba YH, Chen ME, Yang JY, et al. Influencing factors of hospitalization cost of hypertension patients in traditional Chinese medicine hospitals. Front Public Health. 2024;12:1329768. DOI: https://doi.org/10.3389/fpubh.2024.1329768
Oladapo OO, Salako L, Sadiq L, Shoyinka K, Adedapo K, Falase AO. Target-organ damage and cardiovascular complications in hypertensive Nigerian Yoruba adults: a cross-sectional study. Cardiovasc J Afr. 2012;23(7):379-84. DOI: https://doi.org/10.5830/CVJA-2012-021
Kifle ZD, Adugna M, Chanie GS, Mohammed A. Prevalence and associated factors of hypertension complications among hypertensive patients at University of Gondar Comprehensive Specialized Referral Hospital. Clin Epidemiol Global Health. 2022;13:100951. DOI: https://doi.org/10.1016/j.cegh.2021.100951
Ahmad SN, Gul I, Sultan ST. Prevalence and associated factors of hypertension complications among hypertensive patients: A hospital-based study. Int J Acad Med Pharm. 2023;5(1):34-8.
Worku T, Tadesse Y, Hughes P, Lemessa T. Patterns of complications seen in patients with hypertension admitted to tikur anbessa hospital: a retrospective analysis. Ethiop Med J. 2015;2:51-6.
Bayaraa N, Azahar NM, Kitaoka K, Kobayashi Y, Yano Y. African Control of Hypertension through Innovative Epidemiology and a Vibrant Ecosystem (ACHIEVE): a holistic approach for hypertension control in Africa. J Hum Hypertens. 2025;39(2):83-5.
Abdisa L, Girma S, Lami M, Hiko A, Yadeta E, Geneti Y, et al. Uncontrolled hypertension and associated factors among adult hypertensive patients on follow-up at public hospitals, Eastern Ethiopia: A multicenter study. SAGE Open Med. 2022;10:20503121221104442. DOI: https://doi.org/10.1177/20503121221104442
Downloads
Published
How to Cite
Issue
Section
